LivaNova PLC (NASDAQ:LIVN) Receives $64.40 Average Price Target from Analysts

LivaNova PLC (NASDAQ:LIVN) has been assigned an average rating of “Hold” from the five ratings firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $64.40.

Several equities research analysts have recently weighed in on the company. Robert W. Baird upped their price objective on LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, February 22nd. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a research note on Wednesday, March 20th. Barclays lifted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Mizuho restated a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Wednesday, March 27th.

LivaNova Trading Up 0.8 %

LivaNova stock opened at $55.53 on Monday. LivaNova has a 12 month low of $42.75 and a 12 month high of $59.86. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 173.54 and a beta of 0.89. The business has a 50 day moving average price of $54.13 and a two-hundred day moving average price of $50.66. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The firm had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 earnings per share. As a group, equities analysts forecast that LivaNova will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. bought a new position in LivaNova in the third quarter valued at approximately $7,932,000. Kingdon Capital Management L.L.C. bought a new stake in LivaNova in the third quarter valued at about $7,123,000. Vanguard Group Inc. lifted its stake in LivaNova by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after buying an additional 100,133 shares during the period. Barclays PLC boosted its holdings in LivaNova by 15.9% during the third quarter. Barclays PLC now owns 851,870 shares of the company’s stock worth $45,047,000 after buying an additional 116,842 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of LivaNova in the 3rd quarter valued at about $1,672,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.